UPDATE: Oppenheimer Raises Price Target On Curis On Aurigene Collaboration

By: via Benzinga
In a report published Thursday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Curis, Inc. (NASDAQ: CRIS), and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.